EC Cardiology

Introduction: Coronavirus disease-19 (COVID-19) is an infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is a global public health problem since 2019. Respiratory manifestations dominate the clinical picture but cardiovascular involvement is also frequent and often severe. The presence of cardiovascular risk factors and comorbidities is a factor of poor prognosis of the disease.

Method: We carried out a prospective, descriptive and analytical study over a period of one month on patients with COVID-19 seen at the pre-triage of the Joseph Raseta Befelatanana University Hospital Antananarivo. Our objective was to describe the cardiovascular risk factors found during COVID-19 and to determine their association with the severity of COVID-19.

Results: We found a mean age of 50.18 years and a male predominance with a sex ratio of 1,16. Arterial hypertension (49.4%) was the predominant cardiovascular risk factor. Diabetes (p = 0.0004), dyslipidemia (p = 0.0027), hypertension (p = 0.0024), women aged 60 years and over (p = 0.0273) and the number of cardiovascular risk factors greater than two (p = 0.01) were the main factors associated with the severity of the disease.

Conclusion: It is essential to manage these risk factors before and during COVID-19 for a better prognosis of the patients.

Keywords: Antananarivo; COVID-19; Cardiovascular Risk Factors; Severe Form

1. Andreini A. “ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic”. European Society of Cardiology (2020): 119.
2. Alshaikh MK., et al. “Cardiovascular Risk Factors Among Patients Infected with COVID-19 in Saudi Arabia”. Vascular Health and Risk Management 17 (2021): 161‑16
3. Petrilli CM., et al. “Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study”. British Medical Journal 369 (2020): m1966.
4. Collard D., et al. “Cardiovascular risk factors and COVID-19 outcomes in hospitalised patients: a prospective cohort study”. BMJ Open2 (2021): e045482.
5. Li X., et al. “Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan”. Journal of Allergy and Clinical Immunology1 (2020): 110‑118.
6. Silverio A., et al. “Cardiovascular risk factors and mortality in hospitalized patients with COVID-19: systematic review and meta-analysis of 45 studies and 18,300 patients”. BMC Cardiovascular Disorders 1 (2021): 23.
7. Donoghue M., et al. “A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9”. Circulation Research5 (2000): E1-E9.
8. Sharif N., et al. “Prevalence and impact of comorbidities on disease prognosis among patients with COVID-19 in Bangladesh: A nationwide study amid the second wave”. Diabetes Metabolic Syndrome: Clinical Research Reviews4 (2021): 102148.
9. Kaminska H., et al. “Impact of diabetes mellitus on in-hospital mortality in adult patients with COVID-19: a systematic review and meta-analysis”. Acta Diabetologica 8 (2021): 1101‑1110.
10. Liu Y., et al. “Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): a meta-analysis”. Virology Journal 1 (2021): 157.